Exogenous immunoglobulin downregulates T-cell receptor signaling and cytokine production

Pediatric Allergy and Immunology

Volumn 23, Issue 1, 2012, Pages 88-95

  Tawfik, Daniel S ^a   Cowan, Katelyn R ^a   Walsh, Alexandra M ^b   Hamilton, Wendy S ^a   Goldman, Frederick D ^b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Intravenous immunoglobulin (IVIG); T cell cytokines; T cell signaling

Indexed keywords

CD3 ANTIBODY; CD3 ANTIGEN; CD69 ANTIGEN; GAMMA INTERFERON; HUMAN IMMUNOGLOBULIN; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; PHORBOL ESTER; PHYTOHEMAGGLUTININ; T LYMPHOCYTE RECEPTOR;

ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOCOMPETENCE; IMMUNOMODULATION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE SUBPOPULATION; UMBILICAL CORD BLOOD;

ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CYTOKINES; FETAL BLOOD; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-2; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LECTINS, C-TYPE; LYMPHOCYTE ACTIVATION; RECEPTORS, ANTIGEN, T-CELL; SIGNAL TRANSDUCTION; T-LYMPHOCYTE SUBSETS;

EID: 84856384829     PISSN: 09056157     EISSN: 13993038     Source Type: Journal    
DOI: 10.1111/j.1399-3038.2010.01129.x     Document Type: Article

References (27)

1. Ammann AJ, Ashman RF, Buckley RH, et al. Use of intravenous gamma-globulin in antibody immunodeficiency: results of a multicenter controlled trial. Clin Immunol Immunopathol 1982: 22: 60-7.
2. Lederman HM, Winkelstein JA. X-linked agammaglobulinemia: an analysis of 96 patients. Medicine (Baltimore) 1985: 64: 145-56.
3. Quartier P, Debre M, De Blic J, et al. Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: a retrospective survey of 31 patients. J Pediatr 1999: 134: 589-96.
4. Imbach P, Barandun S, Baumgartner C, Hirt A, Hofer F, Wagner HP. High-dose intravenous gammaglobulin therapy of refractory, in particular idiopathic thrombocytopenia in childhood. Helv Paediatr Acta 1981: 36: 81-6.
5. Orange JS, Hossny EM, Weiler CR, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2006: 117: S525-53.
6. Sewell WA, Jolles S. Immunomodulatory action of intravenous immunoglobulin. Immunology 2002: 107: 387-93.
7. Ott VL, Fong DC, Cambier JC. Fc gamma RIIB as a potential molecular target for intravenous gamma globulin therapy. J Allergy Clin Immunol 2001: 108: S95-8.
8. Heidt S, Roelen DL, Eijsink C, Eikmans M, Claas FH, Mulder A. Intravenous immunoglobulin preparations have no direct effect on B cell proliferation and immunoglobulin production. Clin Exp Immunol 2009: 158: 99-105.
9. Sewell WA, North ME, Cambronero R, Webster AD, Farrant J. In vivo modulation of cytokine synthesis by intravenous immunoglobulin. Clin Exp Immunol 1999: 116: 509-15.
10. Ephrem A, Chamat S, Miquel C, et al. Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood 2008: 111: 715-22.
11. Amran D, Renz H, Lack G, Bradley K, Gelfand EW. Suppression of cytokine-dependent human T-cell proliferation by intravenous immunoglobulin. Clin Immunol Immunopathol 1994: 73: 180-6.
12. Kawada K, Terasaki PI. Evidence for immunosuppression by high-dose gammaglobulin. Exp Hematol 1987: 15: 133-6.
13. MacMillan HF, Lee T, Issekutz AC. Intravenous immunoglobulin G-mediated inhibition of T-cell proliferation reflects an endogenous mechanism by which IgG modulates T-cell activation. Clin Immunol 2009: 132: 222-33.
14. Goldman FD, Vibhakar R, Puck JM, et al. Aberrant T-cell antigen receptor-mediated responses in autoimmune lymphoproliferative syndrome. Clin Immunol 2002: 104: 31-9.
15. Goldman F, Hohl RJ, Crabtree J, Lewis-Tibesar K, Koretzky G. Lovastatin inhibits T-cell antigen receptor signaling independent of its effects on ras. Blood 1996: 88: 4611-9.
16. Bjork L, Andersson U, Chauvet JM, Skansen-Saphir U, Andersson J. Quantification of superantaigen induced IFN-gamma production by computerized image analysis-inhibition of cytokine production and blast transformation by pooled human IgG. J Immunol Methods 1994: 175: 201-13.
17. Mankarious S, Lee M, Fischer S, et al. The half-lives of IgG subclasses and specific antibodies in patients with primary immunodeficiency who are receiving intravenously administered immunoglobulin. J Lab Clin Med 1988: 112: 634-40.
18. Sbrana S, Ruocco L, Vanacore R, Azzara A, Ambrogi F. In vitro effects of an immunoglobulin preparation for intravenous use (IVIG) on T-cells activation. Allerg Immunol (Paris) 1993: 25: 35-7.
19. Sticherling M, Trawinski H. Effects of intravenous immunoglobulins on peripheral blood mononuclear cell activation in vitro. Ann N Y Acad Sci 2007: 1110: 694-708.
20. Modiano JF, Amran D, Lack G, et al. Posttranscriptional regulation of T-cell IL-2 production by human pooled immunoglobin. Clin Immunol Immunopathol 1997: 83: 77-85.
21. Tha-In T, Metselaar HJ, Tilanus HW, et al. Superior immunomodulatory effects of intravenous immunoglobulins on human T-cells and dendritic cells: comparison to calcineurin inhibitors. Transplantation 2006: 81: 1725-34.
22. Von Gunten S, Simon HU. Cell death modulation by intravenous immunoglobulin. J Clin Immunol 2010: 30 (Suppl 1): S24-30.
23. Reipert BM, Stellamor MT, Poell M, et al. Variation of anti-Fas antibodies in different lots of intravenous immunoglobulin. Vox Sang 2008: 94: 334-41.
24. Tha-In T, Metselaar HJ, Tilanus HW, et al. Intravenous immunoglobulins suppress T-cell priming by modulating the bidirectional interaction between dendritic cells and natural killer cells. Blood 2007: 110: 3253-62.
25. Kessel A, Ammuri H, Peri R, et al. Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function. J Immunol 2007: 179: 5571-5.
26. Lories RJ, Casteels-Van Daele M, Ceuppens JL, Van Gool SW. Polyclonal immunoglobulins for intravenous use induce interleukin 10 release in vivo and in vitro. Ann Rheum Dis 2004: 63: 747-8.
27. Yamada H, Morikawa M, Furuta I, et al. Intravenous immunoglobulin treatment in women with recurrent abortions: increased cytokine levels and reduced Th1/Th2 lymphocyte ratio in peripheral blood. Am J Reprod Immunol 2003: 49: 84-9.